國家衛生研究院 NHRI:Item 3990099045/5808
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 917401      Online Users : 1439
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/5808


    Title: The effects of co-treatment of 9-cis-Retinoic acid and 15-Deoxy-Delta (12,14)-prostaglandin J2 on microglial activation
    Authors: Hsu, PC;Tsay, HJ;Montine, TJ;Shie, FS
    Contributors: Division of Mental Health and Addiction Medicine
    Abstract: Microglial activation plays an important role in the regulation of neuronal function and contributes to the development of neurodegeneration in Alzheimer's disease (AD). Activation of nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) by an endogenous agonist, 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2), has been shown to be beneficial in many diseases with aberrant immune responses. Here, we report that co-treatment with 15d-PGJ2 and its synergistic partner, 9-cis-retinoic acid (RA), may modulate, but not abolish, microglial immune response activated by beta-amyloid (A beta) and interferon gamma (IFN gamma). The co-treatment of RA and 15d-PGJ2 inhibited A beta/IFN gamma-activated immune response in primary microglia, as evidenced by suppressed expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2); and the effect was not affected by treatment with a PPAR gamma antagonist, GW9662. Data suggest that PPAR gamma activation may not contribute to the anti-inflammatory properties of the co-treatment. The co-treatment promoted microglial A beta clearance in cultures; and the effect can be prevented by blocking PPAR gamma activation using GW9662. The effects of the co-treatment on A beta clearance may be PPAR gamma-dependent. Intriguingly, secretion of microglial pro-nerve growth factor (pro-NGF) was inhibited by A beta/IFN gamma treatment in a dose-dependent manner, suggesting that secretion of microglial pro-NGF may not contribute to the A beta/IFN gamma-activated microglial immune response. Taken together, the co-treatment may be beneficial for AD therapy; however, our data suggest that multiple mechanisms may underlie the beneficial effects of the co-treatment and are not limited to PPAR gamma activation only.
    Date: 2011-05
    Relation: Molecules. 2011 May;16(5):4045-4058.
    Link to: http://dx.doi.org/10.3390/molecules16054045
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1420-3049&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000290955800042
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79957601083
    Appears in Collections:[Feng-Shiun Shie] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000290955800042.pdf538KbAdobe PDF668View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback